# A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer

> **NCT04169997** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Impact Therapeutics, Inc.** · enrollment: 404 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** IMP4927
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04169997
- **Lead sponsor:** Impact Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-24
- **Primary completion:** 2023-03-16
- **Final completion:** 2026-06-30
- **Target enrollment:** 404 (ACTUAL)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04169997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04169997, "A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04169997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*